GCG and type 2 diabetes mellitus: In a study looking at the effects of liraglutide treatment, a glucagon-like peptide-1 agonist known to reduce CVD risk in T2DM patients, plasma ceramides with acyl lengths of 19 and 20 carbon atoms were lowered by GLP-1 treatment, suggesting that the lowering of long acyl chain ceramides may contribute to reported GLP-1 cardio-protection [51].